EGFR and non-small cell lung carcinoma: Furthermore, targeted therapies, such as the first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) like gefitinib, are standard treatment for advanced EGFR mutant NSCLC (Mei et al., 2017).